Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04650581
Title Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
Acronym FINER
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Age Groups: adult | senior
Covered Countries NZL | CAN | AUS

No variant requirements are available.